Interstitial lung disease (ILD) encompasses a large number of entities that cause inflammation and/or fibrosis of the lungs. An estimated 10,000 Canadians have idiopathic pulmonary fibrosis and an additional 30-40,000 have other common forms of fibrotic ILD. Fibrotic ILD reduces quality of life, is often disabling, and increases healthcare costs. The susceptibility to ILD, severity of its manifestations, frequency of adverse treatment effects, and risk of comorbidities all increase with age. Frailty is a major health problem and will be even more important with an aging population.